DarioHealth

DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. The firm solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DarioHealth excels in Q4 2022 with B2B growth and strategic partnerships

DarioHealth's Q4 2022 marked strong financial performance and operational efficiency gains.
Strategic focus on B2B model and multi-condition management driving revenue growth.
Challenges include managing increased expenses and maintaining high gross margin targets.
Opportunities lie in expanding client base, strategic integrations, and revenue diversification.

DarioHealth reports revenue growth and strategic partnerships driving future expansion

DarioHealth's Q1 2023 performance showed revenue growth, improved margins, and strategic focus on B2B.
Strong partnerships with Amwell and Sanofi position the company for multi-condition agreements and revenue growth.
Operational challenges in DTC margins and user comparison require attention for sustained growth.
Opportunities lie in hospitalization reduction, revenue growth from partnerships, and market expansion through Aetna launch.

DarioHealth reports steady Q2 performance, eyes growth through partnerships

DarioHealth's Q2 2023 performance showcased steady B2B2C ARR growth despite flat revenue, with improving gross margins and reduced operating losses, supported by a strong cash position.
The company's strengths lie in strategic partnerships, market fit, and operational efficiency, while facing challenges in revenue growth rates and optimizing expenses.
Opportunities ahead include revenue growth through partnerships and new product launches, leveraging AI for engagement and cost efficiencies, and sustaining a software-driven business model.

DarioHealth reports growth in Q3 2023, eyes revenue diversification

DarioHealth's Q3 2023 showed growth and improved financial metrics.
Strategic partnerships and revenue diversification are key strengths.
Challenges include predicting revenue recognition and cost management.
Opportunities lie in revenue growth and becoming cash flow positive.

DarioHealth reports robust Q4 results, eyes growth through strategic acquisitions

DarioHealth's strong Q4 performance and strategic acquisitions position the company for growth in 2024 and 2025, with a focus on profitability and revenue expansion.
While facing challenges in revenue scaling and cost reduction, the company's strengths in cash position, innovation, and leadership integration provide a solid foundation for success.
Opportunities lie in revenue growth from partnerships and acquisitions, integration synergies, and advancements in digital solutions, driving DarioHealth's path to market differentiation and financial success.

DarioHealth excels in Q1 2024, eyes profitability post Twill merger

DarioHealth's strong Q1 performance driven by B2B2C growth, poised for profitability post Twill merger. Focus on product integration and revenue expansion in key channels.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DarioHealth Corp. is a digital health company which offers a user-centric and multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

NEW YORK, March 1, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced it has entered into a strategic agreement with Sanofi U.S., an innovative global healthcare company. The multi-year, $30 million-dollar agreement, which is subject to certain contingencies, will help accelerate commercial adoption of Dario's full suite of digital therapeutics and drive the expansion of digital health solutions on the Dario platform.

DarioHealth Enters into Strategic Agreement with Sanofi U.S.

NEW YORK, March 1, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that on February 28, 2022 it entered into definitive agreements with institutional investors, including insurance companies located in Israel and primarily consisting of existing shareholders, in connection with a registered direct offering, providing for the issuance of an aggregate of approximately 5,342,013  shares of its common stock (or common stock equivalents in lieu thereof in the form of pre-funded warrants) at a price of $7.49 per share. The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.001 and will expire when exercised in full.

DarioHealth Announced Pricing of its Registered Direct Offering for Aggregate Proceeds of $40 Million Priced At-The-Market Under Nasdaq Rules

NEW YORK, Feb. 9, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced the publication of a retrospective, real-world study demonstrating the impact of managing blood pressure and diabetes together on the same digital platform in the leading peer-reviewed journal for digital medicine and health, the Journal of Medical Internet Research.     To better understand the impact of an integrated, multi-condition digital therapeutics platform, the study compared the results of two propensity-matched groups of people using Dario's digital therapeutic platform to monitor and manage blood sugar levels.

DarioHealth Publishes Clinical Outcomes Demonstrating the Impact of Using a Single Digital Therapeutics Platform for Multiple Conditions

NEW YORK, Feb. 8, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced several new contracts to deliver its digital therapeutics solutions for four new employers. The new accounts are expected to launch during the first and second quarters of 2022.

DarioHealth Announces Four New Employer Contracts

NEW YORK, Jan. 20, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market (the Company), announced it has entered into an agreement to purchase all of the right, title and interest in certain assets of Physimax Technologies Ltd. ("Physimax"), a leading provider of computer vision (CV) technology for Musculoskeletal (MSK) functional screening and predictive risk of injury assessment.

DarioHealth Enters Agreement to Acquire Physimax, a Leading Provider of Validated Computer Vision for Musculoskeletal Health

NEW YORK, Jan. 19, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ-CM: DRIO), a leader in the global digital therapeutics (DTx) market, announced today it has contracted with a large regional health plan (the "Plan") to deliver its digital therapeutic solution for diabetes for eligible Medicaid members in and around the mid-Atlantic region. The contract is expected to contribute to revenue beginning in the second quarter of 2022.

DarioHealth Enters into Agreement with Large Regional Health Plan

NEW YORK, Jan. 18, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) a leader in the global digital therapeutics (DTx) market, today announced that it will host an investor webinar on navigating the emerging digital health trends in 2022 on Wednesday, January 19 th at 8am ET. Join DarioHealth's management and two renowned industry experts from Rock Health and Mercer to better understand how strong tailwinds from the evolving digital health landscape are powering the Company's strategic approach for 2022.

DarioHealth to Host Investor Webinar on Navigating Emerging Digital Health Trends for Strategic Growth in 2022

NEW YORK, Jan. 6, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced two new contracts today to provide its highly personalized digital therapeutics beginning in the first quarter of 2022. The new clients include a large Northeast regional employer in the finance industry set to deploy Dario's full suite of solutions, and a Northeast regional employer in the food industry contracted to deploy Dario's digital therapeutic solution for diabetes.

DarioHealth Announces Two New Contracts within the Employer Market

NEW YORK, Dec. 21, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced a new strategic partnership with a leading employer benefits brokerage (the "Partner") to sell its digital therapeutic solutions for diabetes, hypertension and musculoskeletal health as part of a new premier employee health benefits product for small businesses. The product will be made available to the Partner's more than 2,300 clients beginning in early 2022.

DarioHealth Selected as Exclusive Digital Therapeutics Provider to a Leading Benefits Brokerage

NEW YORK, Dec. 2, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced new contracts today to provide its highly personalized digital therapeutics beginning in the first quarter of 2022. The new clients include a regional employer contract for behavioral health, and a strategic partnership in the provider market that will allow Dario solutions to be sold through a network of practices across the United States.

DarioHealth Announces Two New Contracts within the Employer and Provider Markets

After starting its B2B2C program last year, DarioHealth should finally start to see organic growth in revenues as the company starts to implement its solutions within a large health plan. The company has continued to grow its prospective pipeline despite signing a record amount of new customers within the last few months.

DarioHealth: Moving Towards An Inflection Point

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q3 2021 Results - Earnings Call Transcript

DarioHealth (NASDAQ:DRIO) reported its Q3 earnings results on Monday, November 15, 2021 at 04:30 PM. Here's what investors need to know about the announcement.

Recap: DarioHealth Q3 Earnings

NEW YORK, Nov. 15, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the third quarter of 2021 and provided a corporate and commercial update. "The third quarter provided the strongest validation yet of our strategy of building one of the broadest multi-chronic condition digital health platforms in the industry," stated Erez Raphael, Chief Executive Officer of Dario.

DarioHealth Reports Third Quarter 2021 Results and Operational Highlights

NEW YORK, Nov. 15, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the Company appointed Jerrod Helms to the newly created role of Chief Commercial Officer (CCO) to support the rapid expansion of business in the employer, payer, provider and partnership markets that the company has seen over the last quarter and the anticipated acceleration into 2022. Mr. Helms will report to Rick Anderson, President and General Manager North America.

DarioHealth Appoints Seasoned Health Care Executive Jerrod Helms as Chief Commercial Officer

DarioHealth (NASDAQ:DRIO) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement.

DarioHealth Earnings Preview

NEW YORK, Nov. 11, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has contracted with two new employers and a new provider partner channel to provide the Company's digital therapeutic solutions beginning in the first quarter of 2022. Dario's multi-chronic digital therapeutics platform includes programs for diabetes, pre-diabetes, hypertension, weight management, musculoskeletal and behavioral health integrated across one AI-driven behavior change engine.

DarioHealth Announces Three New Contracts as Growth Continues to Accelerate Across the Employer and Provider Markets

NEW YORK, Nov. 8, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, today announced it would release its financial results for the third quarter ended September 30, 2021 on Monday, November 15, 2021, after the close of trading. The company will host a conference call and webcast on Tuesday, November 16, at 8:30 am Eastern Time.

DarioHealth to Report Third Quarter 2021 Results on Monday, November 15

NEW YORK, Nov. 5, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that management will participate at the following conferences: Credit Suisse 30th Annual Healthcare Conference Format: Investor one-on-one meetingsDate: Tuesday, November 9, 2021 Live Fireside Chat with Erez Raphael, Chief Executive Officer of DarioHealth: 9:40 am EST Craig-Hallum 12th Annual Alpha Select Conference Format: Investor one-on-one meetingsDate: Tuesday, November 16, 2021 Interested parties can access the live and archived webcast of the Credit Suisse presentation on the Events and Presentations section of Dario's Investors website, https://dariohealth.investorroom.com/. About DarioHealth Corp. DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health.

DarioHealth to Participate in Upcoming Investor Conferences

NEW YORK, Nov. 3, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today a new strategic partnership with a leading national benefits administrative platform ("Benefits Platform"), to provide its full suite of integrated digital therapeutic and health solutions to a wide range of employers, beginning in January of 2022. The Benefits Platform will offer Dario's full suite of integrated chronic condition solutions for diabetes, pre-diabetes, hypertension, weight management, musculoskeletal and behavioral health to individuals and organizations through its platform.

DarioHealth Partners with National Group Benefits Platform

NEW YORK, Nov. 1, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has entered into contracts with two prominent regional providers in Hawaii and Georgia for its Remote Patient Monitoring (RPM) services. The two new contracts expand Dario's provider footprint with one of the largest providers in Hawaii, and a metro Atlanta primary care system with multiple locations.

DarioHealth Gathers Momentum in the Provider Market with Two New Contracts for Remote Patient Monitoring Services

NEW YORK, Oct. 27, 2021 /PRNewswire/ -- DarioHealth today announced it has partnered with Virgin Pulse, the leading global provider of digital and live health and wellbeing solutions, making its next-gen digital therapeutic and health solutions available for contract through Virgin Pulse to employers and health plans worldwide. Dario is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health.

DarioHealth joins Virgin Pulse partner network

NEW YORK, Oct. 25, 2021 /PRNewswire/ -- DarioHealth Corp. ("Dario," "DarioHealth" or the "Company") (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has entered into a contract with a U.S. national employer (the "Employer") for the Company's full multi-condition suite of chronic condition management solutions, including diabetes, pre-diabetes, hypertension, musculoskeletal, behavioral health, and digital employee assistance programs.  Enrollment of the Company's multi-condition suite of chronic condition management solutions is expected to begin in the first quarter of 2022, consistent with the Employer's benefit year.

DarioHealth Announces Contract with a U.S. National Employer to Provide Its Full Multi-Condition Suite Digital Therapeutic Solutions

BOSTON, Oct. 18, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today the launch of Dario Move, a new digital physical therapy solution to manage common musculoskeletal (MSK) conditions that drive significant costs for employers and health plans. The solution is being unveiled at HLTH 2021, one of the largest and most important conferences for health innovation, which is taking place in a hybrid format (in-person and virtual) from October 17-20 in Boston.

DarioHealth Unveils its Digital Musculoskeletal Solution Dario Move at HLTH 2021

DarioHealth (NASDAQ: DRIO), a leader in the global digital-therapeutics (“DTx”) market, today announced its entry into an agreement with one of the largest U.S. national health plans to offer its self-insured employer customers the Dario digital behavioral health solution as part of its behavioral health offering. According to the update, initial members are expected on the platform in the fourth fiscal quarter of 2021, with additional rollout anticipated over the course of 2022.

News for DarioHealth Stock (DRIO)